Trastuzumab Increases PFS in Women With HER2/neu Uterine Cancer Trastuzumab Increases PFS in Women With HER2/neu Uterine Cancer

This well-done study should prompt oncologists to consider adding trastuzumab to carboplatin-paclitaxel treatment for women with advanced HER2/neu-positive uterine cancer, says Dr Maurie Markman.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Related Links:

This study presents a comprehensive review of the mechanisms of USC resistance to HER2-targeted therapies and potential strategies to overcome it. PMID: 30265854 [PubMed - in process]
Source: Discovery Medicine - Category: Research Tags: Discov Med Source Type: research
The objectives of this study were to identify the clinicopathological characteristics of GAS and to evaluate HER2 expression in GAS. We retrospectively reviewed 322 cervical cancer cases diagnosed at the Kyoto University Hospital from 2010 to 2016. The incidence, clinical factors including age, stage, and lymph node status, tumor markers, immunoreactive expression of MUC6, HIK1083, and HER2, andHER2 amplification were evaluated. Of the 322 cases of cervical cancer, 13 cases of the adenocarcinoma cases were diagnosed as GAS. Watery discharge, lower abdominal pain, CA19-9 elevation, and lymph node metastasis were frequently ...
Source: Medical Molecular Morphology - Category: Molecular Biology Source Type: research
WEDNESDAY, April 18, 2018 -- For patients with human epidermal growth factor receptor 2 (HER2)/neu-positive uterine serous carcinoma, adding intravenous trastuzumab to treatment with carboplatin-paclitaxel is associated with increased...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
At SGO 2018, an early study showed ‘encouraging’ PFS with trastuzumab added to combination carboplatin/paclitaxel for advanced HER2/neu-overexpressing uterine serous carcinoma.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: Gynecologic Cancers News Conferences/SGO Source Type: news
Abstract Purpose: Carcinosarcomas (CS) are highly aggressive gynecologic malignancies containing both carcinomatous and sarcomatous elements with heterogeneous HER2/neu expression. We compared the efficacy of SYD985, (Synthon Biopharmaceuticals BV), a novel HER2-targeting antibody-drug conjugate (ADC), to Trastuzumab emtansine (T-DM1, Genentech-Roche) against primary uterine and ovarian CS. Experimental Design: Eight primary CS cell lines were evaluated for HER2/neu surface expression by IHC and gene amplification by FISH assays. The in vitro experiments included cytotoxicity, antibody-dependent cellular cytotoxic...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Recently L1CAM was shown to be a promising biomarker for early-stage endometrial carcinoma (EC). As L1CAM expression was found to be related to serous ECs and areas of serous differentiation in endometrioid carcinomas, there is evidence that L1CAM-positive cancers more likely resemble type II carcinomas. Furthermore, expression of growth factor receptor HER2 has been found to be closely associated with serous ECs. We conducted a retrospective study on 142 patients in FIGO stages I and II with endometrioid EC and analyzed L1CAM and HER2 expression by double-staining immunohistochemistry. The association between these 2 tran...
Source: International Journal of Gynecological Pathology - Category: Pathology Tags: Pathology of the Corpus: Original Articles Source Type: research
Approximately 75% of the tumors from breast cancer patients express the estrogen receptor (ER) at diagnosis. Since patients with ER-positive tumors respond to endocrine therapy, determination of the ER status of a patient has important consequences for treatment decision making. The current standard practice to assess ER status is by using immunohistochemical staining of a tumor biopsy. However, the ability to collect serial tumor biopsies during treatment to determine a patient's response to endocrine therapy is limited by the feasibility of performing multiple biopsies. 18F-fluoroestradiol positron emission tomography (F...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
CONCLUSION: Using objective, domain-specific HER2 measurement, 8% of USC and 42% of OSC patients with high HER2 ICD levels do not show uniform overexpression of the ECD. This may be related to the presence of p95 HER2, an oncogenic fragment generated by full protein cleavage or alternative initiation of translation. These observations raise the possibility that USC/OSCs expressing low ECD despite being HER2-positive by ICD measurement, may benefit from therapies directed against the intracellular domain (e.g. lapatinib or afatinib) alone or in combination with extracellular domain-directed drugs (e.g. trastuzumab, pertuzum...
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
Endometrial carcinoma (EC) is traditionally characterized as endometrioid and nonendometrioid based on histopathologic phenotypes. Molecular‐based classifications have been proposed, but are not widely implemented. Herein we examine molecular profiles between EC histologic subtypes. 3133 ECs were submitted between March 2011 and July 2014: 1634 Type I and 1226 Type II. In situ hybridization and immunohistochemistry were used to assess copy number and protein expression of selected genes. Sequenced variants in 47 genes were analyzed using the Illumina TruSeq Amplicon Cancer Panel. Type II EC included 628 cases of uterine ...
Source: International Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Tumor Markers and Signatures Source Type: research
This article is protected by copyright. All rights reserved.
Source: International Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Article Source Type: research
More News: Cancer | Cancer & Oncology | Cancer of the Uterus | Health | Hematology | HER2 | Herceptin | Study | Women